产品
编 号：F283744
分子式：C88H140N20O37
分子量：2070.17
分子式：C88H140N20O37
分子量：2070.17
产品类型
规格
价格
是否有货
结构图
CAS No: 229180-41-0
产品详情
生物活性：
Contulakin G is an O-glycosylated invertebrate neurotensin. Contulakin-G is a weaker agonist for the neurotensin receptor. Contulakin G is also a potent antinociceptive agent.
体内研究：
Contulakin G exhibits potent analgesic activity in three pain models in rats following intrathecal delivery, namely in tail-flick (acute pain), formalin test, and CFA-induced allodynia inflammatory pain.Contulakin G (0-3 nmoL, Intrathecally) significantly decreases flinching behavior in rats.Contulakin G (50-500 nmoL, Intrathecally) produces a dose-dependent increase in the thermally evoked skin twitch latency by 30 min after administration in dogs.Animal Model:Male Holtzman rats (300-375 g)
Dosage:0.03, 0.1, 0.3, and 3 nmol
Administration:Intrathecally, administered as a 10-μL bolus followed by a 10-μL saline flush
Result:Produced a significant decrease in flinching in all phases of the formalin test in rats.
Animal Model:Purpose-bred beagle dogs (9-12 kg)
Dosage:50, 150, or 500 nmol
Administration:Intrathecally
Result:Produced a dose-dependent increase in the thermally evoked skin twitch latency at 30 min after dosing in dogs, which reached statistical difference as compared to vehicle at 500 nmol.
Contulakin G is an O-glycosylated invertebrate neurotensin. Contulakin-G is a weaker agonist for the neurotensin receptor. Contulakin G is also a potent antinociceptive agent.
体内研究：
Contulakin G exhibits potent analgesic activity in three pain models in rats following intrathecal delivery, namely in tail-flick (acute pain), formalin test, and CFA-induced allodynia inflammatory pain.Contulakin G (0-3 nmoL, Intrathecally) significantly decreases flinching behavior in rats.Contulakin G (50-500 nmoL, Intrathecally) produces a dose-dependent increase in the thermally evoked skin twitch latency by 30 min after administration in dogs.Animal Model:Male Holtzman rats (300-375 g)
Dosage:0.03, 0.1, 0.3, and 3 nmol
Administration:Intrathecally, administered as a 10-μL bolus followed by a 10-μL saline flush
Result:Produced a significant decrease in flinching in all phases of the formalin test in rats.
Animal Model:Purpose-bred beagle dogs (9-12 kg)
Dosage:50, 150, or 500 nmol
Administration:Intrathecally
Result:Produced a dose-dependent increase in the thermally evoked skin twitch latency at 30 min after dosing in dogs, which reached statistical difference as compared to vehicle at 500 nmol.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备